Leerink Partnrs Has Bearish Outlook for RXRX Q2 Earnings

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) - Analysts at Leerink Partnrs reduced their Q2 2025 EPS estimates for shares of Recursion Pharmaceuticals in a research note issued to investors on Thursday, July 17th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings of ($0.29) per share for the quarter, down from their prior forecast of ($0.27). The consensus estimate for Recursion Pharmaceuticals' current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for Recursion Pharmaceuticals' Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.33) EPS, FY2026 earnings at ($0.86) EPS and FY2027 earnings at ($0.35) EPS.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). The firm had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The firm's revenue was up 7.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.39) EPS.

A number of other research firms have also weighed in on RXRX. Morgan Stanley began coverage on shares of Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 target price for the company. Needham & Company LLC reaffirmed a "buy" rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Tuesday, July 8th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Recursion Pharmaceuticals presently has an average rating of "Hold" and an average price target of $7.00.

Recursion Pharmaceuticals Stock Performance

Recursion Pharmaceuticals stock traded down $0.17 on Monday, reaching $6.26. 22,734,360 shares of the stock were exchanged, compared to its average volume of 33,033,296. The stock has a market cap of $2.54 billion, a PE ratio of -3.54 and a beta of 0.91. The company has a current ratio of 4.11, a quick ratio of 4.11 and a debt-to-equity ratio of 0.02. Recursion Pharmaceuticals has a twelve month low of $3.79 and a twelve month high of $12.36. The firm has a fifty day moving average price of $5.08 and a two-hundred day moving average price of $5.98.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Ensign Peak Advisors Inc raised its position in shares of Recursion Pharmaceuticals by 0.3% during the fourth quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company's stock valued at $2,774,000 after buying an additional 1,300 shares during the last quarter. Farther Finance Advisors LLC increased its stake in Recursion Pharmaceuticals by 21.1% in the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after acquiring an additional 1,353 shares during the period. Summit Investment Advisors Inc. increased its stake in Recursion Pharmaceuticals by 7.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company's stock valued at $176,000 after acquiring an additional 1,875 shares during the period. Clear Creek Financial Management LLC increased its stake in Recursion Pharmaceuticals by 9.8% in the first quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company's stock valued at $113,000 after acquiring an additional 1,907 shares during the period. Finally, GAMMA Investing LLC increased its stake in Recursion Pharmaceuticals by 39.0% in the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock valued at $38,000 after acquiring an additional 2,026 shares during the period. Institutional investors and hedge funds own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.